ArticleCurrent microbiology2010
Screening and evaluation of human intestinal lactobacilli for the development of novel gastrointestinal probiotics.
Article in Current microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 48 citations in OpenAlex.
- Collection of human bacteria at University of Tartu, Estonia.Microbiology resource announcements · 2026Article
- Comprehensive Safety Assessment ofMicroorganisms · 2025Article
- In Vitro Evaluation ofLife (Basel, Switzerland) · 2022Article
- In vitro screening of EPS-producingFood science & nutrition · 2022Article
- Probiotics, their action modality and the use of multi-omics in metamorphosis of commensal microbiota into target-based probiotics.Frontiers in nutrition · 2022Review
- In Vitro Anti-staphylococcal and Anti-inflammatory Abilities of Lacticaseibacillus rhamnosus from Infant Gut Microbiota as Potential Probiotic Against Infectious Women Mastitis.Probiotics and antimicrobial proteins · 2021Article
- Selection of Potential Probiotic Bacteria from Exclusively Breastfed Infant Faeces with Antagonistic Activity Against Multidrug-Resistant ESKAPE Pathogens.Probiotics and antimicrobial proteins · 2021Article
- Probiotic Properties and Neuroprotective Effects ofInternational journal of molecular sciences · 2020Article
- Comparative genomics of eight Lactobacillus buchneri strains isolated from food spoilage.BMC genomics · 2019Article
- Biodiversity of Intestinal Lactic Acid Bacteria in the Healthy Population.Advances in experimental medicine and biology · 2016Review
- Protein O-glucosylation in Lactobacillus buchneri.Glycoconjugate journal · 2014Article
- Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses.BMC infectious diseases · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to screen intestinal lactobacilli strains for their advantageous properties to select those that could be used for the development of novel gastrointestinal probiotics. Ninety-three isolates were subjected to screening procedures. Fifty-nine percent of the examined lactobacilli showed the ability to auto-aggregate, 97% tolerated a high concentration of bile (2% w/v), 50% survived for 4 h at pH 3.0, and all strains were unaffected by a high concentration of pancreatin (0.5% w/v). One Lactobacillus buchneri strain was resistant to tetracycline. None of the tested strains caused lysis of human erythrocytes. Six potential probiotic strains were selected for safety evaluation in a mouse model. Five of 6 strains caused no translocation, and were considered safe. In conclusion, several strains belonging to different species and fermentation groups were found that have properties required for a potential probiotic strain. This study was the first phase of a multi-phase study aimed to develop a novel, safe and efficient prophylactic and therapeutic treatment system against gastrointestinal infections using genetically modified probiotic lactobacilli.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.